Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
Colorectal cancer (CRC) is one of the leading cancers in terms of prevalence and mortality. Almost 1/4 of patients with CRC have metastases at the initial presentation. The survival rate of this group of patients remains low. With the onset of the COVID-19 pandemic, cancer patients have faced diffic...
Guardado en:
Autores principales: | Marina I. Sekacheva, Anastasia S. Fatyanova, Daur A. Meretukov, Angelina V Zhilenkova, Aleksandr S. Rusanov, Aleksandr A. Rozhkov, Anastasiia A. Guryanova, Nikolay N. Bagmet |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/74b49f25f4074c698a61ce570af6f103 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
por: M. I. Sekacheva, et al.
Publicado: (2020) -
A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
por: Simona De Summa, et al.
Publicado: (2021) -
Regorafenib in metastatic colorectal cancer: more data for clinical decisions
por: Vladislav V. Petkau, et al.
Publicado: (2021) -
Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Hong Zhou, et al.
Publicado: (2021) -
Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer
por: Ilfad Blazevic, et al.
Publicado: (2020)